奈诺沙星及其他抗菌药物对人体及分离菌株的活性及其明确的耐药机制。
Activities of Nemonoxacin and Other Antimicrobial Agents Against Human and Isolates and Their Defined Resistance Mechanisms.
作者信息
Wang Na, Liu Wancheng, Zhou Yunheng, Liu Yang
机构信息
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Fudan University, Shanghai, China.
出版信息
Front Microbiol. 2019 Aug 13;10:1890. doi: 10.3389/fmicb.2019.01890. eCollection 2019.
Nemonoxacin, a newly developed non-fluorinated quinolone (NFQ), selectively inhibits bacterial DNA topoisomerase activity. However, its activities against have rarely been studied to date. Herein, the activities of nemonoxacin were evaluated against clinical isolates of 50 , 20 , and 77 spp., and they were compared to fluoroquinolones, tetracyclines, and macrolides. Nemonoxacin MICs (μg/ml) ranged from 0.03 to 0.25 for , 0.25 to 8 for , and 0.06 to >16 for spp., and all of the ranges are similar to those of fluoroquinolones. The activity of nemonoxacin against was not affected by resistance to macrolides in the strains tested, but it seems to have the same resistant mechanism as fluoroquinolones. In addition, minimum bactericidal concentrations (MBC) of nemonoxacin to were within two dilutions of the MIC values, indicating a bactericidal effect on . Nemonoxacin merits further study for treating infections caused by these organisms.
奈诺沙星是一种新开发的非氟喹诺酮（NFQ），可选择性抑制细菌DNA拓扑异构酶活性。然而，迄今为止，其对[具体细菌名称未给出]的活性很少被研究。在此，评估了奈诺沙星对50株[具体细菌名称未给出]、20株[具体细菌名称未给出]和77株[具体细菌名称未给出]临床分离株的活性，并将其与氟喹诺酮类、四环素类和大环内酯类药物进行了比较。奈诺沙星对[具体细菌名称未给出]的最低抑菌浓度（MIC，μg/ml）范围为0.03至0.25，对[具体细菌名称未给出]为0.25至8，对[具体细菌名称未给出]菌株为0.06至>16，所有这些范围与氟喹诺酮类药物相似。在测试菌株中，奈诺沙星对[具体细菌名称未给出]的活性不受对大环内酯类耐药性的影响，但它似乎与氟喹诺酮类药物有相同的耐药机制。此外，奈诺沙星对[具体细菌名称未给出]的最低杀菌浓度（MBC）在MIC值的两个稀释度范围内，表明对[具体细菌名称未给出]有杀菌作用。奈诺沙星在治疗由这些微生物引起的感染方面值得进一步研究。
Zotero 插件